STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Neuronetics, Inc. (STIM) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Momentum (C). The rating has held at C+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B- (3.0) | C+ (2.5) | C+ (2.8) | C (2.5) | C+ (2.6) | C+ (2.7) |
| 2026-11-08 | B- (3.0) | C+ (2.5) | C+ (2.7) | B (3.3) | C+ (2.6) | C+ (2.8) |
| 2026-11-01 | B- (3.0) | C (2.4) | B- (2.9) | B- (3.0) | C+ (2.7) | C+ (2.8) |
| 2026-10-25 | B- (3.0) | C (2.4) | C+ (2.8) | B+ (3.8) | C+ (2.6) | B- (2.9) |
| 2026-10-18 | B- (3.0) | C (2.4) | C+ (2.8) | B+ (3.6) | C+ (2.6) | B- (2.9) |